We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-5.86%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$188M
AUM Growth
+$104M
Cap. Flow
+$102M
Cap. Flow %
54.21%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$108M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$5.95M
2
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
+$362K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$115M 60.87%
+5,158,161
New +$108M
RPTX
2
DELISTED
Repare Therapeutics
RPTX
$32M 17%
2,646,657
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$4.68B
$22.6M 12.03%
498,558
– –
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$7.6M 4.04%
506,823
– –
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$6.13M 3.26%
3,561,150
– –
PASG icon
6
Passage Bio
PASG
$14.7M
$3.26M 1.73%
247,988
– –
ALGS icon
7
Aligos Therapeutics
ALGS
$26.3M
$1.73M 0.92%
92,815
– –
UTRS
8
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$275K 0.15%
4,184
-79,501
-95% -$362K
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
– –
-543,753
Closed -$5.95M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q3 2023 Portfolio in Review

As of Q3 2023, Versant Venture Management held 9 positions worth $188M, up 123% from $84.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $102M of net new capital in Q3 2023, opening 1 new position. Its largest new stake was RayzeBio, Inc. Common Stock: 5,158,161 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Minerva Surgical, Inc. Common Stock, an estimated $362K trimmed.

  • Versant Venture Management's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 5,158,161 shares worth $115M.
  • Versant Venture Management's biggest Q3 2023 reduction was Minerva Surgical, Inc. Common Stock, cutting an estimated $362K.
  • Versant Venture Management fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $5.95M.
  • Versant Venture Management's ten largest holdings make up 100% of its $188M portfolio in Q3 2023.
  • Versant Venture Management opened 1 new position and closed 1 in Q3 2023.
  • Versant Venture Management's portfolio value rose 123% quarter-over-quarter to $188M.

Based on Versant Venture Management's 13F filing for Q3 2023, filed 3 Nov 2023.